Literature DB >> 35755087

Statistical estimation and comparison of group-specific bivariate correlation coefficients in family-type clustered studies.

Jingqin Luo1, Feng Gao1, Jingxia Liu1, Guoqiao Wang2, Ling Chen2, Anne M Fagan3, Gregory S Day4, Jonathan Vöglein5, Jasmeer P Chhatwal6, Chengjie Xiong3.   

Abstract

Bivariate correlation coefficients (BCCs) are often calculated to gauge the relationship between two variables in medical research. In a family-type clustered design where multiple participants from same units/families are enrolled, BCCs can be defined and estimated at various hierarchical levels (subject level, family level and marginal BCC). Heterogeneity usually exists between subject groups and, as a result, subject level BCCs may differ between subject groups. In the framework of bivariate linear mixed effects modeling, we define and estimate BCCs at various hierarchical levels in a family-type clustered design, accommodating subject group heterogeneity. Simplified and modified asymptotic confidence intervals are constructed to the BCC differences and Wald type tests are conducted. A real-world family-type clustered study of Alzheimer disease (AD) is analyzed to estimate and compare BCCs among well-established AD biomarkers between mutation carriers and non-carriers in autosomal dominant AD asymptomatic individuals. Extensive simulation studies are conducted across a wide range of scenarios to evaluate the performance of the proposed estimators and the type-I error rate and power of the proposed statistical tests. Abbreviations: BCC: bivariate correlation coefficient; BLM: bivariate linear mixed effects model; CI: confidence interval; AD: Alzheimer's disease; DIAN: The Dominantly Inherited Alzheimer Network; SA: simple asymptotic; MA: modified asymptotic.
© 2021 Informa UK Limited, trading as Taylor & Francis Group.

Entities:  

Keywords:  Bivariate correlation coefficient; bivariate linear mixed effects model; confidence interval; hypothesis testing; parameter estimation; type-I error/size and power

Year:  2021        PMID: 35755087      PMCID: PMC9225315          DOI: 10.1080/02664763.2021.1899141

Source DB:  PubMed          Journal:  J Appl Stat        ISSN: 0266-4763            Impact factor:   1.416


  35 in total

1.  Estimating correlation coefficient between two variables with repeated observations using mixed effects model.

Authors:  Anuradha Roy
Journal:  Biom J       Date:  2006-04       Impact factor: 2.207

2.  Cerebrospinal fluid biomarkers in Alzheimer disease: a fractional improvement?

Authors:  Douglas Galasko
Journal:  Arch Neurol       Date:  2003-09

3.  Cerebrospinal fluid biomarkers in the evaluation of Alzheimer disease.

Authors:  Marcel M Verbeek; Marcel G M Olde Rikkert
Journal:  Clin Chem       Date:  2008-10       Impact factor: 8.327

4.  Bivariate correlation coefficients in family-type clustered studies.

Authors:  Jingqin Luo; Gina D'Angela; Feng Gao; Jimin Ding; Chengjie Xiong
Journal:  Biom J       Date:  2015-09-11       Impact factor: 2.207

Review 5.  [The DIAN study].

Authors:  Hiroyuki Shimada
Journal:  Brain Nerve       Date:  2013-10

Review 6.  Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β(1-42) and τ proteins as Alzheimer disease biomarkers.

Authors:  Ju-Hee Kang; Magdalena Korecka; Jon B Toledo; John Q Trojanowski; Leslie M Shaw
Journal:  Clin Chem       Date:  2013-03-21       Impact factor: 8.327

7.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease.

Authors:  Randall J Bateman; Chengjie Xiong; Tammie L S Benzinger; Anne M Fagan; Alison Goate; Nick C Fox; Daniel S Marcus; Nigel J Cairns; Xianyun Xie; Tyler M Blazey; David M Holtzman; Anna Santacruz; Virginia Buckles; Angela Oliver; Krista Moulder; Paul S Aisen; Bernardino Ghetti; William E Klunk; Eric McDade; Ralph N Martins; Colin L Masters; Richard Mayeux; John M Ringman; Martin N Rossor; Peter R Schofield; Reisa A Sperling; Stephen Salloway; John C Morris
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

Review 8.  Identifying and validating biomarkers for Alzheimer's disease.

Authors:  Christian Humpel
Journal:  Trends Biotechnol       Date:  2010-10-23       Impact factor: 19.536

9.  Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease.

Authors:  Niklas Mattsson; Philip S Insel; Susan Landau; William Jagust; Michael Donohue; Leslie M Shaw; John Q Trojanowski; Henrik Zetterberg; Kaj Blennow; Michael Weiner
Journal:  Ann Clin Transl Neurol       Date:  2014-07-19       Impact factor: 4.511

10.  Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples.

Authors:  Tobias Skillbäck; Henrik Zetterberg; Kaj Blennow; Niklas Mattsson
Journal:  Alzheimers Res Ther       Date:  2013-10-14       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.